Table 1.
Patient characteristics
| All patients (n = 79) | |
|---|---|
| Gender, n (%) | |
| Female | 36 (45.6) |
| Male | 43 (54.4) |
| Age at first cycle, median (range) | 60.7 (26.1–82.3) |
| Site of primary tumor, n (%) | |
| Small intestine | 30 (38.0) |
| Pancreas | 26 (32.9) |
| Adrenal glanda | 6 (7.6) |
| Lung | 6 (7.6) |
| Colon | 2 (2.5) |
| Stomach | 1 (1.3) |
| Esthesioneuroblastoma | 1 (1.3) |
| Unknown | 7 (8.9) |
| Metastases, n (%) | |
| Liver | 66 (83.5) |
| Lymph nodes | 51 (64.6) |
| Bone | 29 (36.7) |
| Lung | 9 (11.4) |
| Otherb | 25 (31.6) |
| Body size descriptors, mean ± SD (range) | |
| Weight (Kg) | 72.1 ± 16.6 (42.6–121.0) |
| Lean body weight (Kg) | 52.4 ± 9.9 (35.4–81.2) |
| Body surface area (m2) | 1.8 ± 80.2 (1.4–2.5) |
| eGFR (ml/min/1.73 m2), mean ± SD (range) | 86.3 ± 22.2 (42.0–154.1) |
| Number of cycles, n (%) | |
| 1 | 8 (10.1) |
| 2 | 6 (7.6) |
| 3 | 16 (20.3) |
| 4 | 38 (48.1) |
| 5 | 3 (3.8) |
| 6 | 6 (7.6) |
| 7 | 1 (1.3) |
| 8 | 1 (1.3) |
| Type of cycles, n (%) | |
| Empiric only | 23 (29.1) |
| Personalized only | 45 (57.0) |
| Mixed | 11 (13.9) |
eGFR estimated glomerular filtration rate, PRRT peptide receptor radionuclide therapy
aThree patients with pheochromocytoma and three patients with paraganglioma
bPeritoneum, ovary, subcutaneous, pleura, meninges